Like most malignancies, colorectal cancer is an extraordinarily heterogeneous disease. From surgically curable early-stage tumors to almost uniformly lethal diffuse metastatic disease, the treatment and outcome of colorectal cancer runs a wide spectrum. Unlike most malignancies, this spectrum of treatment and outcome exists within the group of patients diagnosed with stage IV disease. Patients who have widely disseminated, multiorgan, metastatic disease are treated with palliative chemotherapy with a median survival of approximately 2 years. 1 To add further complexity and heterogeneity to this, up to 10 % of patients treated with palliative chemotherapy survive 5 years, and the group of patients with resected liver and/or lung metastases have an associated 5-year survival rate of *50 %. 2, 3 By contrast, *1 in 5 patients who have limited and resectable liver metastases is cured by hepatic resection. 4 Both early death and prolonged disease-free survival are therefore possible in patients with ''stage IV'' colorectal cancer.
It seems logical that stage IV colorectal cancer should have its own staging system, either incorporated into the larger staging of all of colorectal cancer or on its own. Many biomarkers, including circulating tumor cells (as reviewed by Groot Koerkamp et al., in this issue of the Annals of Surgical Oncology) have been studied but have not been promising enough to be incorporated into routine practice. Various staging schemes have been suggested and even the AJCC provides a limited grouping of M1 disease, but none have been accepted as clinically relevant. 5 Numerous staging systems for patients with resectable liver metastases have been proposed-all based on risk scores incorporating various pathologic and clinical prognostic indicators. Unfortunately, these staging systems have not been successful since they have not consistently worked across institutions and have not been sufficiently reliable. 6 Of course, staging systems used for liver metastases do not apply to the broader situation of metastatic colorectal cancer. The cornerstone of a good staging scheme consists of objective, reliable, and consistent biomarkers that provide clinically meaningful survival prognostication and prediction of who will benefit from various treatment strategies. While many prognostic biomarkers exist for specific clinical situations among patients with stage IV colorectal cancer (isolated liver metastases being the best example), little work has gone into the staging of the broader context of metastatic colorectal cancer.
In this issue of the Annals of Surgical Oncology, Groot Koerkamp et al. 7 present an exhaustive and meticulous meta-analysis of the prognostic role of circulating tumor cells (CTC) in patients with metastatic colorectal cancer. Although rigorous inclusion definitions are provided, the reality is that the studies in this review are very heterogenous. The analysis includes studies on patients with resectable disease and those with diffuse metastases receiving palliative chemotherapy. Timing and location of blood draws (some include bone marrow aspirations), mechanisms of CTC detection, exposure to different therapies, as well as different selection criteria for study subjects are just some of the factors varying from study to study. The authors should be commended for performing thoughtful, complete, sophisticated, and what appear to be appropriate statistical measures to account for the almost innumerable sources of bias throughout this study. The principal finding of the study is that detectable CTCs in the blood are a powerful prognostic indicator of survival. In general, patients with detectable CTCs have a 2.5-fold higher chance of earlier death regardless of treatment and the other sources of bias and variability-as best these could be accounted for. It is, of course, impossible to make definitive conclusions based on this meta-analysis. What we can say is that the presence of CTCs is a promising biomarker associated with a poor outcome in patients who have metastatic colorectal cancer. Perhaps more importantly, this study raises the possibility that the prognostic power of the presence of CTCs may be equally relevant across the spectrum of stage IV colorectal cancer.
So, where do we go from here? Unfortunately, there is a huge amount of work to do. The optimal system to detect CTCs has not been established, and with ongoing technologic advances more systems are likely forthcoming. With the development of newer detection systems, sensitivity and specificity may vary. For this technology to have widespread applicability, a consistent and optimized detection system needs to be developed. More importantly, the role of CTCs in specific clinical scenarios has to be prospectively studied. Can CTCs be used to define a group of patients with ''resectable'' metastases who should not undergo resection? Can CTCs be used to monitor the effectiveness of systemic chemotherapy or predict what chemotherapy would be most effective? Can CTCs be used to help stage patients with metastatic colorectal cancer?
In the end, we are reminded that stage IV colorectal cancer is a disease with many possible outcomes ranging from rapid death to cure. We are also reminded that our ability to predict which patient will experience which outcome is relatively limited. The detection of CTCs is a potentially promising biomarker that could contribute to the staging of this ''disease'' and is deserving of prospective study.
